Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.31 |
| ▸ | SELP | P16109 | 4/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411309 | 0.93 | L3MBTL1 (0.36) | NT5EL3MBTL1ALDH1A1BCHETMEM97 | |
| SCHEMBL12411312 | 0.86 | L3MBTL1 (0.36) | L3MBTL1 | |
| SCHEMBL10148625 | 0.83 | NT5E (0.39) | NT5EL3MBTL1ALDH1A1ABCB1BCHE | |
| SCHEMBL15481395 | 0.81 | L3MBTL1 (0.39) | NT5EL3MBTL1ALDH1A1 | |
| SCHEMBL13458032 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL12411311 | 0.78 | NT5E (0.36) | NT5EL3MBTL1ALDH1A1ABCB1BCHE | |
| SCHEMBL7151120 | 0.77 | L3MBTL1 (0.45) | L3MBTL1BCHETMEM97SIGMAR1 | |
| SCHEMBL15483272 | 0.76 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1ABCB1BCHE | |
| SCHEMBL16378350 | 0.75 | ALDH1A1 (0.37) | NT5EALDH1A1ABCB1BCHE | |
| SCHEMBL1647937 | 0.74 | NT5E (0.47) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166078-A1 | OLIGOSACCHARIDE COMPOUNDS FOR USE IN MOBILISING STEM CELLS | ENDOTIS PHARMA | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166078-A1 | OLIGOSACCHARIDE COMPOUNDS FOR USE IN MOBILISING STEM CELLS | CXCL12, CCL11, FUT6 | NT5E 4131/4885L3MBTL1 3508/4885ALDH1A1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.